Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Herbal mix plus tenofovir shows promise for hepatitis b control

NCT ID NCT01198860

Disease control Sponsor: Nguyen Thi Trieu, MD Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved This study
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a combination of four herbs (Phyllanthus urinaria, Adenosma glutinosum, Eclipta prostrata, and ascorbic acid) plus the drug tenofovir can help control hepatitis B over the long term. The treatment aims to strengthen the immune system and reduce virus levels. Adults with chronic or acute hepatitis B who have had the virus for at least 6 months and have stable liver function may join.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Lead sponsor

An individual researcher

The lead sponsor is a named person rather than an organisation.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Inclusion Criteria: * Males and females ≥ 18 years of age with chronic and acute hepatitis B. * Hepatitis B surface antigen (HBsAg)(+) for a minimum of 6 months prior to entry. * Hepatitis B envelope antigen (HBeAg)(+) or (-) at baseline. * Patients having treated or untreated * Patients with compensated liver function (Child-Pugh score ≤ 6). * Informed writted consent. Exclusion Criteria: * Any serious or active medical or psychiatric illness which, in the opinion of the investigator, would interfere with patient treatment, assessment or compliance with the protocol. or cytokine-based therapies with possible activity in hepatitis B disease within 6 months prior to study screening. * Organ or bone marrow transplant recipients. * Evidence of active liver disease to operate. * Received immunoglobulins, interferon or other immune e to other causes (e.g., Wilson's disease, hemochromatosis, autoimmune hepatitis, hepatitis C, hepatitis D or HIV.) * Patients taking parenteral (intravenous or intramuscular or subcutaneous) or oral steroids, immuno-suppressant therapies or chemotherapeutic agents within 2 months of study screening or expected to receive these agents during the course of the study. * Clinically relevant alcohol or drug use or history of alcohol or drug use considered by the investigator to be sufficient to hinder compliance with treatment, follow up procedures or evaluation of adverse events. * Hepatocellular carcinoma. * Serious concurrent medical illness other than hepatitis B. * History of hypersensitivity to nucleoside analogues. * Women of childbearing potential not practising adequate contraception. * Pregnancy or lactation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute hepatitis B are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute hepatitis B virus infection chronic hepatitis B virus infection hepatitis B virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic hepatitis B

Contacts and locations

Locations

  • Saigon Biopharma Company Limited

    Hồ Chí Minh, Ho Chi Minh City, 700000, Vietnam

  • Saigon Biopharma LLC

    Wilmington, Delaware, 19801-6601, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.